This episode of Digital Pathology Today™ our guest is Nathan Buchbinder, Chief Product Officer and Co-founder at Proscia.   

One of the biggest pieces of news we've gotten in 2022 is the announcement of new CPT codes from the American Medical Association specifically for digital pathology. What are CPT codes? Why should we care? How will these new codes help us to elevate the practice of anatomic pathology and allow us to more concretely articulate a value proposition for digital pathology?

 Our guest is Nathan Buchbinder, Chief Product Officer and cofounder at Proscia. We discuss the new CPT codes and much more. We get a current lay of the land for digital pathology in mid-2022. How far have we come in the past five years or so? How far have we come in the past year - which has seen dramatic changes and acceleration in many areas. How do the US and Europe differ in adoption and outlook and what are some continuing barriers to the adoption of digital pathology? e digital transformation in pathology is well underway but what kind of opportunities does this present to us?  We've heard all the buzz words such as machine learning artificial intelligence and heard all the hype about enhanced workflows and making pathologists’ lives easier.  What is the future practice of pathology going to look like?

Nathan Buchbinder co-founded Proscia, a leading digital and computational pathology software company in 2014, where he currently serves as the Chief Product Officer. During his tenure, Proscia has earned recognition as a category leader, bringing to market best-in-class image management software and artificial intelligence applications for laboratory medicine. 

Nathan is passionate about medical devices, and has worked on the product development, IP, and business development elements of devices in fields ranging from neonatal care, stem cells therapies, emergency medicine, and pathology software. His experience in this industry ranges from organizing small animal studies to product management. Nathan earned his Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and his Master degree in Biomedical Innovation Development at the Georgia Institute of Technology.